At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Aug 16, 2026 at 20:00 ET
HUTCHMED announced positive Phase III SAFFRON trial results showing savolitinib (ORPATHYS) plus osimertinib (TAGRISSO) significantly improved progression-free survival and overall survival vs chemotherapy in EGFR-mutant NSCLC patients with MET-driven resistance after TAGRISSO progression. This is a high-impact catalyst for global registration of the combination, addressing a large unmet need in a biomarker-defined population with no prior oral targeted option.
- SAFFRON Phase III met primary endpoint of PFS and key secondary endpoint of OS with statistical significance and clinical meaningfulness
- Trial enrolled 338 patients across 29 countries in 230 centers
- Combination addresses MET overexpression/amplification, which occurs in ~34% of patients after third-generation EGFR TKI progression
- ORPATHYS plus TAGRISSO already approved in China based on SACHI Phase III; SAFFRON supports global registrations
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access